Early screening and diagnosis of prostate cancer based on the innovative care for chronic conditions framework.
- Author:
Han-Jing ZHU
1
;
Liang DONG
2
;
Bin ZHAO
3
;
Feng ZHANG
4
;
Rong LI
4
;
Cheng-Ye ZHU
4
;
Jia MAO
5
;
Zhen-Ying YANG
5
;
Yin-Jie ZHU
2
;
Wei XUE
2
Author Information
1. Department of Nursing, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medical, Shanghai 200127, China.
2. Department of Urology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medical, Shanghai 200127, China.
3. Department of Urology, Pujin Community Health Service Center of Minhang District, Shanghai 201112, China.
4. Department of General Medicine, Pujin Community Health Service Center of Minhang District, Shanghai 201112, China.
5. Department of General Medicine, Huamu Community Health Service Center of Shanghai Pudong New Area, Shanghai 201204, China.
- Publication Type:Journal Article
- Keywords:
Innovative Care for Chronic Conditions Framework;
tiered diagnosis and treatment;
prostate cancer screening;
prostate-specific antigen
- MeSH:
Humans;
Male;
Prostatic Neoplasms/diagnosis*;
Early Detection of Cancer;
Prostate-Specific Antigen/blood*;
Aged;
China;
Mass Screening;
Middle Aged;
Chronic Disease
- From:
National Journal of Andrology
2025;31(3):229-233
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To construct an integrated management model for early screening and diagnosis of PCa based on the Innovative Care for Chronic Conditions Framework (ICCC) and the 1+1 contract-based tiered diagnosis and treatment system (TDTS) in China.
METHODS:Based on the 1+1 contract-based TDTS platform, we conducted PCa screening for the male residents aged 60 years and above during health check-ups in Pujin Community Health Center from January 1, 2023 to December 31, 2023. For those with abnormal total prostate-specific antigen (tPSA) ≥ 4 μg/L, we promptly referred them to higher-level hospitals for further diagnosis and treatment via the two-way referral green channel platform and information sharing service using the 1+1 contract model. We further analyzed the relevant data on screening and diagnosis.
RESULTS:A total of 4 080 males aged 71.39±5.059 years received PCa screening from January to December 2023. PSA screening was performed in 43.96% of the male residents, revealing 654 cases of PSA abnormality, with a PSA positivity rate of 16.03%, which was higher than that found in the previous large-scale PCa screenings in other regions of China. Among the males with PSA abnormality, 292 (44.65%) expressed their willingness for medical referral, while the others did not seek further medical attention for reasons of being asymptomatic, low awareness of the disease, no accompany for medical visits, and concerns about further costs of diagnosis and treatment. Prostate biopsy was recommended to 154 cases after further examinations, which was accepted by 92 (59.74%). Fifty-eight cases were diagnosed with Pa, and thedetection rate reached 63.04%.
CONCLUSION:The integrated management model for PSA examination-based early screening and diagnosis of PCa using the 1+1 contract-based TDTS platform is plays a significant role in enhancing people's awareness and knowledge of PCa and improving the early detection rate of the malignancy.
